Challenging ideas to drive progress

Millions of COPD patients remain symptomatic despite treatment with available therapies. Novel treatments are urgently needed to address this issue. In the US alone, total annual medical costs, indirect and direct, relating to COPD are about $50 billion. We believe our product will have a significant role helping patients who remain symptomatic on existing treatments for COPD.

We may seek strategic collaborations with leading biopharmaceutical companies to develop and commercialize ensifentrine. These partnerships could provide significant funding to advance the development of ensifentrine while allowing us to benefit from the development and commercialization expertise of our collaborators.

Initially, we are developing ensifentrine for the US market and seeking strategic partnerships in other regions. We have formed a $219 million strategic collaboration with Nuance Pharma to develop and commercialize ensifentrine in Greater China. The region has an estimated 100 million COPD patients.

We are developing a fixed-dose combination formulation with ensifentrine and glycopyrrolate, a long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD via a nebulizer.
In addition to nebulizers, handheld inhalers are frequently used in the treatment of respiratory diseases. Our pipeline includes Dry powder inhaler (DPI) and pressurized metered dose inhaler (pMDI) formulations of ensifentrine, which provide lifecycle and collaboration opportunities.

We believe ensifentrine has potential to be an effective treatment for many respiratory conditions. Our pipeline is focused on indications with unmet medical needs including NCFB, cystic fibrosis and asthma.

We are leveraging our expertise in respiratory diseases to in-license or acquire additional clinical-stage product candidates. We are seeking assets with the potential to become novel treatments for respiratory diseases with significant unmet medical needs.